Do you have ulcerative colitis and feel your current medications are not working for you?

The Lucent study – a clinical trial to assess the safety and effectiveness of a new drug, mirikizumab, in conventional-failed and biologic-failed patients with moderately to severely active ulcerative colitis

The primary purpose of your participation in this study is not to treat you for your condition but to help answer the following research question: How mirikizumab compares with placebo in helping patients with UC?

Mirikizumab is an experimental treatment. This means that it is not an approved treatment for UC in Australia, by the Therapeutic Goods Administration.

Anticipated date that enrolment will close: December 2020

Who can take part

  • People with a clinical diagnosis of UC for at least 3 months
  • UC must be at least moderate to severe
  • Failed conventional therapy or failed biologic therapy

Exclusion criteria

  • People with Crohn's disease
  • Any history of cancer in the gastrointestinal tract

What is involved for you

  • medical history
  • physical exam
  • electrocardiogram (ECG)
  • weight, height, blood pressure, pulse, heart rate
  • health questionnaires
  • blood samples
  • urine test
  • colonoscopy with biopsy collection
  • stool tests
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
Nicola Dalgliesh
03 9342 8441
Zafirah Khan
03 9342 8995